Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transposase-accessible chromatin regions of MDA-MB-453 cells expressing ectopic wild-type, Y537S, or K303R ER alpha.

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE191065 | GEO | 2022/12/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Genome-wide analysis of transposase-accessible chromatin regions of MDA-MB-453 cells expressing ectopic wild-type, Y537S, or K303R ER alpha.

Project description:We analyzed the chromatin state of MDA-MB-453 cells expressing wild-type, Y537S, or K303R ER alpha by ATAC-seq, and identified K303R-related disordered chromatin opening which has Fox-binding motifs.

2022-12-16 | GSE191057 | GEO

Genome-wide analysis of ectopically expressed wild-type, Y537S, or K303R ER alpha-binding genomic regions in MDA-MB-453 cells.

Project description:We analyzed the wild-type, Y537S, or K303R ER alpha-binding genomic regions ectopically expressed in MDA-MB-453 cells by ChIP-seq, and identified K303R-related disordered ERa binding and chromatin opening at Fox motif regions.

2022-12-16 | GSE191058 | GEO

Breast cancer cell line MDA-MB-453 response to DHT

Project description: Not available

| S-ECPF-GEOD-28789 | biostudies-other

Effect of 5a-dihydrotestosterone on breast cancer cell line MDA-MB-453

Project description: Not available

| S-ECPF-GEOD-28305 | biostudies-other

Multifunctional Cu<sub>2-x</sub>Te Nanocubes Mediated Combination Therapy for Multi-Drug Resistant MDA MB 453.

Project description: Not available

| S-EPMC5075932 | biostudies-literature

CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM).

Project description: Not available

| S-EPMC8158361 | biostudies-literature

AR heterogeneity in TNBC MDA-MB-453 cells

Project description:Triple-negative breast cancer (TNBC) is aggressive and difficult, and few targeted therapies are available to treat this patient population. The androgen receptor (AR) has emerged as a potential target in breast cancer. Newer generation AR inhibitors, such as Seviteronel (Sevi), are unique in their ability to inhibit AR both directly and by blocking upstream androgen synthesis. The purpose of this study was to investigate the pre-clinical activity of Sevi in TNBC and further explore the effectiveness of targeting both androgen biosynthesis and AR activity in combination with other downstream acting agents. AR overexpressing (AR+) TNBC cell lines, xenografts and androgen responsive patient-derived xenograft (PDX) models were using to show how effectively Sevi inhibits AR activity and cell/tumor proliferation. Single cell RNA-sequencing of the AR+ cell line MDA-MB-453 illustrated heterogeneity in AR levels and identified cell cycle pathway activation in ARHigh versus ARLow expressing cells. Combination treatment with the cell cycle CDK4/6 inhibitor abemaciclib and Sevi showed synergy in AR+ TNBC cells and increased effectiveness, compared to each drug alone, in an AR+ TNBC xenograft model. While cell cycle inhibitors have been approved for use in hormone-receptor positive breast cancer, our studies suggest that these drugs may be equally effective in AR+ TNBC cells, especially when combined with AR antagonists. Implications. These data suggest that targeting AR signaling at multiple points throughout the pathway may be an effective was to treat patients with AR+ TNBC.

2020-06-12 | GSE152315 | GEO

Effect of over-expression of AR-V7 in MDA-MB-453 breast cancer cells

Project description: Not available

| S-ECPF-GEOD-65738 | biostudies-other

Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ER?Y537S and ER?D538G mutations.

Project description: Not available

| S-EPMC6351074 | biostudies-literature

Down-Regulation of Ca2+-Activated K? Channel KCa1.1 in Human Breast Cancer MDA-MB-453 Cells Treated with Vitamin D Receptor Agonists.

Project description: Not available

| S-EPMC5187883 | biostudies-literature